Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN versus R P MYCIN.
PEDIAMYCIN vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may be bacteriostatic or bactericidal depending on concentration and organism.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
250-500 mg orally every 6 hours; maximum 2 g/day.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. In patients with severe hepatic impairment, half-life may be prolonged to 5-6 hours. The short half-life necessitates frequent dosing (every 6-8 hours) to maintain therapeutic levels.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
PEDIAMYCIN (erythromycin ethylsuccinate) is primarily excreted via the biliary route (60-70% as unchanged drug and metabolites) with significant fecal elimination. Renal excretion accounts for only 5-15% of the dose, mostly as inactive metabolites. Less than 5% is excreted unchanged in urine.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic